Enzyme Replacement Therapy
- Name
- Enzyme Replacement Therapy
- Accession Number
- DBCAT000147
- Description
Not Available
- Drugs
Drug Drug Description Imiglucerase A form of recombinant human beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease. Alglucerase A form of recombinant beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease. Taliglucerase alfa A hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease. Asfotase alfa An enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP). Elapegademase A recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency. Avalglucosidase alfa A lysosomal glycogen-specific enzyme that is used to treat patients one year of age and older with late-onset Pompe disease, or lysosomal acid alpha-glucosidase (GAA) deficiency. Agalsidase alfa A recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide. Velmanase alfa A recombinant human lysosomal alpha-mannosidase used to treat non-neurological symptoms of mild to moderate alpha-mannosidosis. Olipudase alfa A recombinant human acid sphingomyelinase used to treat Acid Sphingomyelinase Deficiency (ASMD) in children and adults. Pegunigalsidase alfa A recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease. Cipaglucosidase alfa A recombinant human acid alpha-glucosidase used to treat late-onset Pompe disease in adults. - Drugs & Drug Targets